Institute News
Most Popular
MacTel Project 2021 Update
LOWY MEDICAL RESEARCH INSTITUTE - LMRI This past year has surely been an interesting and challenging one. We hope that you and your family, friends, neighbors, and coworkers were able to weather the events safely. Despite the many challenges prese...
Positive Phase 3 Topline Results Announced for NT-501 Implant in MacTel
November 2, 2022 Neurotech Pharmaceuticals, Inc. announces positive Phase 3 topline results for NT-501 implant in macular telangiectaisa type 2 (MacTel). (Cumberland, RI) Clinically relevant and statistically significant primary results with t...
Phase 3 Trial Currently Enrolling MacTel Patients
Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi-center trial...
Results of NT-501 Phase 2 Study Published
January 16, 2019, Cumberland, RI and La Jolla, CA. The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been published in the journal o...
Lowy Medical Research Institute scientists find cause of debilitating eye disease
15-year effort points to treatments to help MacTel patients and offers potential new insights into other eye diseases LA JOLLA, CA–September 11, 2019– Scientists at the Lowy Medical Research Institute (LMRI) have discovered one cause of a progre...